What Aptose Biosciences does

Aptose Biosciences Inc. is a clinical-stage biopharmaceutical company incorporated under the Canada Business Corporations Act and headquartered in Toronto, Canada, with operational offices in San Diego, California. The company is publicly listed on the Toronto Stock Exchange (TSX: APS) and OTC markets (OTC: APTOF) and is currently the subject of a going-private acquisition by Hanmi Pharmaceutical Co. Ltd., announced November 19, 2025 at C$2.41 per share, with shareholder and Alberta Court approval secured in March 2026 and closing targeted for June 2026 pending Korean regulatory clearances.

Aptose develops small-molecule kinase inhibitors targeting hematologic malignancies, with its lead asset being tuspetinib (TUS), an oral myeloid kinase inhibitor (MKI) that potently inhibits SYK, FLT3 (mutated and wildtype), JAK, c-KIT(mut), and RSK2. Tuspetinib is being evaluated in the Phase 1/2 TUSCANY trial as triplet therapy with venetoclax and azacitidine (TUS+VEN+AZA) for newly diagnosed AML patients ineligible for induction chemotherapy; interim data reported an 86.2% composite complete response rate across 29 evaluable patients and 100% CRc in TP53-mutated/complex-karyotype patients at the 160 mg dose. A second asset, luxeptinib (LUX), was returned to original licensor CGI Invites Co., Ltd. in May 2026, narrowing the pipeline to tuspetinib ahead of the Hanmi closing. Aptose licensed tuspetinib from Hanmi in November 2021, and Hanmi has since become both the largest shareholder (~20% pre-acquisition) and sole material financial backer, providing over $41 million in debt facilities over 18 months.

Aptose is pre-revenue with no commercialized products and operates a cost-intensive clinical development model funded by equity issuances and Hanmi debt advances; the company reported a net loss of $25.5 million in FY2025 and $7.6 million in Q1 2026 with $4.1 million in cash at March 31, 2026. The go-to-market strategy centers on advancing tuspetinib through Phase 1/2 at 10 leading U.S. academic clinical sites, with commercialization to be pursued post-acquisition through Hanmi's resources. Customers in the traditional sense are absent; the company's primary counterparty is Hanmi Pharmaceutical, and its end-users are AML patients enrolled in clinical trials rather than paying accounts.

Name

Aptose Biosciences

Legal name

Aptose Biosciences Inc.

Website

https://aptose.com

Company type

Public

Founded year

1986

Operating status

Operating

Headcount range

11–50 employees

Short description

Aptose Biosciences is a clinical-stage biopharmaceutical company developing tuspetinib, an oral multi-kinase inhibitor for acute myeloid leukemia. Pre-revenue and currently being acquired by Hanmi Pharmaceutical (C$2.41/share) with closing targeted for June 2026.

Ownership category

akta.pro rank

Product category

Hematology Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Hematology drug development
• Kinase inhibitor therapeutics
• Oncology clinical trials
• Precision oncology medicines
• AML treatment pipeline

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-commercial / Clinical Stage Revenue: Aptose is a clinical-stage biotechnology company with no commercialized products generating revenue. The company relies on financing activities, including equity offerings, private placements, and debt facilities from Hanmi Pharmaceutical, to fund ongoing clinical development of tuspetinib and luxeptinib.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Aptose Biosciences is a clinical-stage biopharmaceutical company developing proprietary small-molecule kinase inhibitor drug candidates for hematologic malignancies, principally acute myeloid leukemia (AML). Its lead candidate tuspetinib (TUS) is an oral multi-kinase inhibitor being evaluated in the Phase 1/2 TUSCANY trial as triplet therapy (TUS+VEN+AZA) for newly diagnosed AML patients ineligible for induction chemotherapy. A second candidate, luxeptinib (LUX), a BTK/FLT3 inhibitor for B-cell malignancies and AML/MDS, had its license returned to CGI Invites Co., Ltd. in May 2025.

Product overview

Aptose Biosciences is a clinical-stage precision oncology company developing a pipeline of small molecule cancer therapeutics focused on hematologic malignancies. The core product portfolio includes: (1) Tuspetinib (TUS), an oral myeloid kinase inhibitor targeting SYK, FLT3, JAK, and c-KIT(mut), being developed for AML in the Phase 1/2 TUSCANY trial as triplet therapy with venetoclax and azacitidine, and previously studied in the APTIVATE monotherapy/combination trial; (2) Luxeptinib (LUX), a lymphoid and myeloid kinome inhibitor targeting BTK and FLT3, in Phase 1a/b trials for B-cell malignancies (CLL, NHL) and AML/MDS. Note: Aptose has returned the license rights for Luxeptinib to CGI Invites Co., Ltd.

Differentiator

Problem solved

Functional benefit

Products and services

• Tuspetinib (TUS) Tuspetinib is a potent oral inhibitor of key kinases operative in myeloid malignancies, including SYK, FLT3, JAK, c-KIT(mut), and others. It is being developed for acute myeloid leukemia (AML) treatment both as monotherapy and in combination therapy (TUS+VEN+AZA triplet).
• Luxeptinib (LUX) Luxeptinib is a potent non-covalent inhibitor of wildtype and mutant forms of BTK, as well as multiple oncogenic signaling pathways operative in CLL and other B-cell malignancies, and was also being developed as a myeloid kinome inhibitor (MKI) for AML and MDS.

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• CGI Invites Co., Ltd. (CGI)minorOthers · 13 May 2025Luxeptinib (formerly CG-806) was licensed from CGI under a 2016 agreement (updated in 2018). Aptose and CGI entered into a Termination of License Agreement in May 2025, with Aptose returning the license rights to CGI. The compound is now being returned to its original developer.

Scale indicators6 records

Recent moves8 records

Expansion highlights4 records

Direct peers

• Astellas Pharma: Astellas markets Xospata (gilteritinib), an FLT3 inhibitor approved for relapsed/refractory FLT3-mutated AML. It is a direct competitor to Aptose's tuspetinib, which also targets FLT3 (mutated and wildtype) within its multi-kinase inhibition profile, addressing overlapping AML patient populations.
• Daiichi Sankyo: Daiichi Sankyo markets Vanflyta (quizartinib) for FLT3-mutated AML, both in frontline combination with chemotherapy and as maintenance therapy. It competes directly with Aptose's tuspetinib in FLT3-driven AML and represents a meaningful comparator in FLT3 inhibitor efficacy and safety.
• Servier: Servier (which acquired Agios's oncology business) markets Tibsovo (ivosidenib) for IDH1-mutated AML. It is a direct competitor in the molecularly stratified AML space, and its established commercial infrastructure in AML offers a relevant comparator for go-to-market strategy.
• Kura Oncology: Kura Oncology is a clinical-stage precision oncology company developing KO-539, a menin inhibitor for NPM1-mutated and KMT2A-rearranged AML. It is a closely comparable clinical-stage AML peer with similar development stage, target indication overlap, and pipeline concentration risk profile.
• GlycoMimetics: GlycoMimetics is a clinical-stage hematology-focused company developing uproleselan and other E-selectin-based therapeutics for AML. It is a direct peer in clinical-stage AML drug development with comparable size, public-market status, and indication focus.

Broad incumbents

• AbbVie: AbbVie (with Genentech/Roche) markets venetoclax (VENCLEXTA), which is a core component of Aptose's TUS+VEN+AZA triplet. While not a direct molecular competitor, AbbVie is the dominant player in AML combination therapy and any changes to venetoclax pricing, access, or labeling would materially impact Aptose's commercial prospects.
• Bristol-Myers Squibb: Bristol-Myers Squibb operates a broad oncology franchise including AML therapeutics (e.g., azacitidine co-promotion and idasanutlin development). As a major incumbent, it competes for AML market share and provides relevant comparison points on commercial scale, regulatory strategy, and combination trial design.

Emerging players

• Aprea Therapeutics: Aprea Therapeutics is a clinical-stage oncology company developing eprenetapopt (APR-246) for TP53-mutated malignancies, including AML/MDS. It is a relevant peer given the shared focus on TP53-mutated patient populations — a key differentiation area for Aptose's tuspetinib.
• Relay Therapeutics: Relay Therapeutics is a clinical-stage precision oncology company leveraging computational approaches to develop targeted therapies including RLY-4008 and PI3Kα inhibitors. It is a comparable precision-oncology peer with similar clinical-stage profile and investor base dynamics.

Others

• Schrödinger: Schrödinger is a computational drug discovery platform company that develops small molecule therapeutics internally and partners with pharma. It is thematically related as a platform-enabled small molecule drug developer, and its internal pipeline includes oncology programs, providing a relevant comparator for capital-efficient drug discovery models.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/aptose-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds13 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptose Biosciences